DE602004012279T3 - Katecholderivate zur behandlung von krebs - Google Patents

Katecholderivate zur behandlung von krebs Download PDF

Info

Publication number
DE602004012279T3
DE602004012279T3 DE602004012279T DE602004012279T DE602004012279T3 DE 602004012279 T3 DE602004012279 T3 DE 602004012279T3 DE 602004012279 T DE602004012279 T DE 602004012279T DE 602004012279 T DE602004012279 T DE 602004012279T DE 602004012279 T3 DE602004012279 T3 DE 602004012279T3
Authority
DE
Germany
Prior art keywords
cancer
use according
och
alkyl
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004012279T
Other languages
German (de)
English (en)
Other versions
DE602004012279T9 (de
DE602004012279D1 (de
DE602004012279T2 (de
Inventor
John C. Rancho Sante Fe REED
Maurizio San Diego PELLECCHIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BURNHAM INST LA JOLLA
BURNHAM INSTITUTE LA JOLLA
Original Assignee
BURNHAM INST LA JOLLA
BURNHAM INSTITUTE LA JOLLA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BURNHAM INST LA JOLLA, BURNHAM INSTITUTE LA JOLLA filed Critical BURNHAM INST LA JOLLA
Publication of DE602004012279D1 publication Critical patent/DE602004012279D1/de
Application granted granted Critical
Publication of DE602004012279T2 publication Critical patent/DE602004012279T2/de
Publication of DE602004012279T9 publication Critical patent/DE602004012279T9/de
Publication of DE602004012279T3 publication Critical patent/DE602004012279T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602004012279T 2003-06-25 2004-06-25 Katecholderivate zur behandlung von krebs Expired - Lifetime DE602004012279T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48288603P 2003-06-25 2003-06-25
US482886P 2003-06-25
PCT/US2004/020569 WO2005009434A2 (en) 2003-06-25 2004-06-25 Compounds and methods for inducing apoptosis in cancer cells

Publications (4)

Publication Number Publication Date
DE602004012279D1 DE602004012279D1 (de) 2008-04-17
DE602004012279T2 DE602004012279T2 (de) 2009-07-16
DE602004012279T9 DE602004012279T9 (de) 2010-01-28
DE602004012279T3 true DE602004012279T3 (de) 2010-07-15

Family

ID=34102647

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004012279T Expired - Lifetime DE602004012279T3 (de) 2003-06-25 2004-06-25 Katecholderivate zur behandlung von krebs
DE602004028880T Expired - Lifetime DE602004028880D1 (de) 2003-06-25 2004-06-25 Analoga von Apogossypol zur Verwendung in der Behandlung von Krebs

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004028880T Expired - Lifetime DE602004028880D1 (de) 2003-06-25 2004-06-25 Analoga von Apogossypol zur Verwendung in der Behandlung von Krebs

Country Status (13)

Country Link
US (3) US7812058B2 (enExample)
EP (2) EP1653943B3 (enExample)
JP (2) JP2007524633A (enExample)
AT (2) ATE478663T1 (enExample)
AU (1) AU2004258867B2 (enExample)
CA (1) CA2529507C (enExample)
DE (2) DE602004012279T3 (enExample)
DK (1) DK1653943T4 (enExample)
ES (2) ES2303096T7 (enExample)
PL (1) PL1653943T6 (enExample)
PT (1) PT1653943E (enExample)
SI (1) SI1653943T1 (enExample)
WO (1) WO2005009434A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US7354928B2 (en) * 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
PL1653943T6 (pl) 2003-06-25 2009-02-27 The Burnham Inst La Jolla Pochodne katecholu do leczenia raka
CA2561303C (en) * 2004-03-25 2011-01-18 The Regents Of The University Of Michigan Gossypol co-crystals and the use thereof
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
EP2197273B1 (en) * 2007-10-01 2014-09-24 Ascenta Therapeutics, Inc. Process for preparing r-gossypol l-phenylalaninol dienamine
US9115061B2 (en) * 2007-10-19 2015-08-25 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
FR2924712B1 (fr) 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
WO2010019914A2 (en) * 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
BRPI1016102A2 (pt) 2009-04-15 2015-09-01 Sanford Burhnham Medical Res Inst Inibidores de proteínas anti-apoptótica baseados em naftaleno
US8772264B2 (en) 2009-08-04 2014-07-08 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
EP2485721A4 (en) 2009-10-08 2016-05-18 Sanford Burnham Med Res Inst APOGOSSYPOLON DERIVATIVES AS ANTICREMENTS
EP2956470A4 (en) * 2013-02-15 2016-12-07 Univ Michigan Regents COMPOSITIONS AND METHODS RELATED TO PREVENTING DOT1L RECRUITMENT BY MLL FUSION PROTEINS
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JP2018512450A (ja) * 2015-03-19 2018-05-17 ウェンディ アン エプスタインＥＰＳＴＥＩＮ， Ｗｅｎｄｙ Ａｎｎｅ 女性の性的障害を治療するための化合物及び剤型
RU2654711C1 (ru) * 2017-07-10 2018-05-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, обладающее апоптоз-индуцирующей активностью
KR102614471B1 (ko) * 2018-04-20 2023-12-14 나이키 이노베이트 씨.브이. 플레이트들 및 개재된 유체 충전 블래더를 구비하는 솔 구조체 및 제조 방법
CN110128290B (zh) * 2019-05-10 2022-04-29 江苏耐雀生物工程技术有限公司 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用
CA3155694A1 (en) * 2019-09-24 2021-04-01 Genetec Inc. Intermediary device for daisy chain and tree configuration in hybrid data/power connection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
US5804567A (en) * 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
JP2005502579A (ja) * 2000-12-15 2005-01-27 ワックヴォム リミテッド 新生血管形成に関連する状態を処置するための方法および組成物
ATE474568T1 (de) * 2001-05-30 2010-08-15 Univ Michigan Synergistische kombination von (-) -gossypol mit docetaxel oder paclitaxel zur behandlung von krebs.
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
PL1653943T6 (pl) 2003-06-25 2009-02-27 The Burnham Inst La Jolla Pochodne katecholu do leczenia raka

Also Published As

Publication number Publication date
DK1653943T4 (da) 2008-12-01
US20120269901A1 (en) 2012-10-25
CA2529507C (en) 2011-08-09
US8367644B2 (en) 2013-02-05
JP2012025767A (ja) 2012-02-09
WO2005009434A2 (en) 2005-02-03
EP1938816A2 (en) 2008-07-02
EP1938816B1 (en) 2010-08-25
ES2303096T7 (es) 2009-06-18
ATE387911T1 (de) 2008-03-15
EP1938816A3 (en) 2008-08-06
US20110111057A1 (en) 2011-05-12
US7812058B2 (en) 2010-10-12
DK1653943T3 (da) 2008-06-23
DE602004012279T9 (de) 2010-01-28
US20050027000A1 (en) 2005-02-03
ES2303096T3 (es) 2008-08-01
PT1653943E (pt) 2008-05-23
PL1653943T3 (pl) 2008-09-30
DE602004012279D1 (de) 2008-04-17
ATE478663T1 (de) 2010-09-15
CA2529507A1 (en) 2005-02-03
JP2007524633A (ja) 2007-08-30
AU2004258867A1 (en) 2005-02-03
PL1653943T6 (pl) 2009-02-27
SI1653943T1 (sl) 2008-08-31
WO2005009434A3 (en) 2005-06-09
DE602004028880D1 (de) 2010-10-07
EP1653943B1 (en) 2008-03-05
EP1653943A2 (en) 2006-05-10
ES2351581T3 (es) 2011-02-08
AU2004258867B2 (en) 2010-02-18
DE602004012279T2 (de) 2009-07-16
EP1653943B3 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
DE602004012279T2 (de) Katecholderivate zur behandlung von krebs
DE60218443T2 (de) Jasmonate enthaltende therapeutische zusammensetzungen für die behandlung von krebs
DE60011755T2 (de) Calciumkanalblocker als antikrebsmittel
DE60034957T2 (de) Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2-familie exprimieren
DE69327330T2 (de) Verfahren zum bekämpfen der pneumocystis carinii pneumonie und dafür verwendbare verbindungen
US20090156668A1 (en) Ginkgolide Compounds, Compositions, And Extracts, And Uses Thereof
EP1113795B1 (de) Tryptophanylester und deren n-acyl-derivate zur prävention und therapie von erkrankungen, die durch oxidationsprozesse verursacht oder verstärkt werden
DE69907419T2 (de) Antitumorwirkstoffe
DE69028320T2 (de) Illudin-analoge, verwendet als antitumormittel
Takagi et al. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176
EP3248981B1 (en) C14-hydroxyl esterified amino acid derivatives of triptolide, and preparation method and use thereof
DE69612056T2 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
AT502055A1 (de) Behandlung von tumoren
DE60012750T2 (de) Neue xanthon derivate, deren herstellung und verwendung als arzneimittel
EP1986634A2 (de) Synergistische pharmazeutische zusammensetzung enthaltend ein peptid mit 2 bis 5 aminosäuren
DE112004002032B4 (de) Concentricolid und seine Derivate, Verfahren zum Herstellen pharmazeutischer Zusammensetzungen umfassend deren Verwendung
DE69107616T2 (de) Phenolisches amin als antimelanoma- und depigmentierungsmittel.
WO2009103807A1 (de) Kupfer-organokomplexe, deren verwendung als antitumormittel und zum schutz gesunden gewebes vor ionisierender strahlung
EP2161024A1 (de) Kombinationspräparat zur Behandlung von Krebs
WO2007030848A2 (de) Nichtfluoreszierende chlorophyllkataboliten
KR102105412B1 (ko) 항암 활성을 갖는 크로만 화합물 및 이를 유효성분으로 포함하는 암 예방 및 치료용 약학 조성물
WO2007051622A1 (de) Leitstrukturen für zytostatische verbindungen auf basis von spiroverbindungen
DE102006048362A1 (de) Synergistische pharmazeutische Zusammensetzung
Axelrod et al. I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
EP0607774A2 (de) Verwendung von Leflunomid zur Hemmung von Interleukin 1 alpha

Legal Events

Date Code Title Description
8364 No opposition during term of opposition